In a cytogenetic and comparative genomic hybridization (CGH) study of 38 hepatoblastomas, we found gain of 1q in 17 tumors (44.7%), that of 2/2q in 14 (36.8%), that of 20/20q in 9 (23.7%) and that of 8/8q in 8 (21.0%), loss of 4q in 4 (10.5%) and no DNA copy changes with normal karyotype or no mitotic cells in 11 (28.9%). Eleven tumors with 2/2q gain detected by CGH had a total chromosome 2 gain, a partial 2q gain, or a total chromosome 2 gain with an augmented partial 2q region; the common region for DNA copy gain was 2q24. Two-color fluorescence in situ hybridization (FISH) analyses using probes covering the centromere of chromosome 2 or HOXD13 (2q31) confirmed the CGH findings, and showed that the common region for gain in 2q was centromeric to HOXD13. Event-free survival (EFS) ± ± ± ±standard error (SE) at 5 years was lowest in patients with 2q gain [37 ± ± ± ±15%], highest in those with no DNA copy changes [82± ± ± ±12%], and intermediate in those with DNA copy changes other than 2q gain [74 ± ± ± ±13%] (P = = = =0.0549). Multivariate analysis showed that 2q gain was an independent factor predicting a poor outcome. These findings suggest the presence of a growth-promoting gene or an oncogene in the 2q24 chromosome band, and a tumor suppressor gene in terminal 4q, which have important roles in the development and progression of hepatoblastoma.
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Hepatoblastoma is a malignant hepatic tumor in children, which occurs mostly in the first 3 years of life. 1) Due to the rare incidence, cytogenetic and moleculargenetic studies in hepatoblastoma have been limited compared with those of other childhood tumors. Common cytogenetic abnormalities reported included trisomies of chromosome 2, 5, 8 and/or 20, and 1q trisomy, which is occasionally associated with 4q deletion; namely, der(4)t(1;4)(q12;q34). [2] [3] [4] [5] Recently, comparative genomic hybridization (CGH) analysis has been performed in 3 series of hepatoblastomas, which confirmed cytogenetic findings reported previously. [6] [7] [8] Although most hepatoblastomas are sporadic, they also occur in association with Beckwith-Wiedemann (B-W) syndrome and familial adenomatous polyposis (FAP). 9, 10) APC mutation and/or loss of heterozygosity in the APC locus were reported in some children with both sporadic and the FAP-associated hepatoblastomas. 11, 12) More recently, mutation of the β-catenin gene was reported in approximately half of the sporadic hepatoblastomas examined. 13) Although previous cytogenetic and CGH analyses reported common chromosomal regions of gain or loss, only one study attempted to determine the prognostic implication of these genetic changes, 8) because of the small number of hepatoblastomas included in each series. We performed cytogenetic and CGH analysis in 38 children with hepatoblastoma, and identified frequent DNA copy changes in distinct chromosomal regions including 1q and 2q. Moreover, fluorescence in situ hybridization (FISH) and chromosome analyses narrowed down the region of 2q gain, and revealed a cytogenetic mechanism of DNA copy gain in 2q in one tumor. We also found that 2q gain was associated with poor outcome of hepatoblastoma patients. (Table I ) Tumors were obtained from 38 Japanese children with hepatoblastoma who underwent biopsy or surgery between March 1989 and September 1999. Thirteen and 25 tumors were obtained before and after chemotherapy, respectively. There were 21 males and 17 females, ranging in age from 3 months to 8 years with a median age of 1 year. Patients were staged according to the system proposed by the Children's Cancer Study Group. 14) The majority of patients were treated according to the protocols of the Japan Hepatoblastoma Study Group. 15) The pathological diagnosis was made based on routine hematoxylin/eosin-stained slides by Cytogenetic studies Chromosomes were studied as described previously. 17) Karyotypes were described according to the International System for Human Cytogenetic Nomenclature (ISCN) 1995.
MATERIALS AND METHODS

Patients and samples
18)
CGH study Genomic DNA was isolated from 38 hepatoblastoma tumors and from lymphocytes of a normal male and a normal female. Tumor DNA was labeled by nick translation with biotin-11-dUTP, and control DNA was labeled with digoxigenin-11-dUTP. Four hundred to 800 ng of labeled tumor and normal DNA were combined with 15 µg of human Cot1 DNA and precipitated with ethanol. The precipitate was resuspended in 12 µl of the hybridization mixture, denatured, and hybridized to normal metaphase cells for 48 h. Hybridized DNA fragments were detected with avidin-fluorescein isothiocyanate (FITC) and antidigoxigenin rhodamine. Chromosomes were counterstained with 4′,6-diamino-2-phenylindole dihydrochloride (DAPI). Digital images of FITC, rhodamine and DAPI fluorescence were acquired separately with a cooled chargecoupled device (CCD) camera. The ratios of the FITC-torhodamine signal intensity were calculated using the automated CGH analysis software (CytoVision, Applied Imaging, Newcastle, UK). The ratio profiles were averaged from at least 10 metaphase cells. A chromosomal region was considered to be overrepresented (gain) or underrepresented (loss), if the average ratio profile was above 1.25 or below 0.75, respectively. FISH studies To detect the copy number of chromosome 2 and gain of the 2q31 chromosomal region, we used an α satellite DNA probe covering the centromeric region of chromosome 2 (CEP 2, Spectrum Orange) (VYSIS, Downers Grove, IL), and a BAC probe (RBP1) covering HOXD13, which is located in 2q31. 19) The BAC probe was labeled with biotin (bio)-16-dUTP (Boehringer, Mannheim, Germany) by nick translation. Interphase and metaphase cells were stained with DAPI. Two-color FISH was performed as described. 20) Statistical analysis Patients were grouped according to various biological and clinical aspects of the disease. Event-free and overall survivals for each group of patients were estimated on October 30, 1999 using the KaplanMeier method, and compared using log-rank tests. Time to failure was defined as the interval between surgery or preoperative chemotherapy and relapse or death from any cause. Failure to achieve complete remission by chemotherapy or gross residual disease after the initial surgical procedure was considered an event at day 1.
Influence of various biological and clinical factors on event-free and overall survival was estimated using the Cox proportional-hazards model. The analysis was performed using the SPSS software for Windows, version 7.5.1 (SPSS, Chicago, IL).
RESULTS
Cytogenetic findings
Of 38 hepatoblastomas in which cytogenetic analysis was performed, 9 (23.7%) had no mitotic cells, 13 (34.2%) had only normal mitotic cells, and 16 (42.1%) had clonal abnormal cells (Table II) . Twelve tumors had trisomy 2 or trisomy or pentasomy 2q (Fig. 1) , 12 had trisomy, tetrasomy, or hexasomy 1q, 6 had trisomy 8, and 4 had trisomy 20. Two tumors had an unbalanced 1;4 translocation resulting in a deletion of 4q34-4qter and 1q trisomy. CGH findings Findings from CGH analysis of 38 hepatoblastomas are presented in Table II (Fig. 1) , and one (No. 1408) had gains of 2pter-2q24 and 2q32-qter. The most common region for increased DNA copy number was 2q24.
Combined findings of cytogenetic and CGH analyses
Of 29 tumors from which mitotic cells were obtained, 6 tumors had normal karyotypes and normal CGH patterns, 7 had normal karyotypes and abnormal CGH patterns, 3 had abnormal karyotypes and normal CGH patterns, and 13 had abnormal karyotypes and abnormal CGH patterns. Of the other 9 tumors from which no mitotic cells were obtained, 5 and 4 had normal and abnormal CGH patterns, respectively.
Combined findings of cytogenetic and CGH analyses showed gain of 1q in 17 tumors (44.7%), that of 2/2q in 14 (36.8%), that of 20/20q in 9 (23.7%) and that of 8/8q in 8 (21.0%), and loss of 4q in 4 (10.5%). The most common regions for gain were 1q32-1qter and 2q24, and the most common region for loss was 4q34-4qter. Interphase and metaphase FISH findings Two-color FISH analysis using probes covering the centromere of chromosome 2 or HOXD13 (2q31) was performed in 9 of (Fig. 3 ). Normal chromosome 2 had 1 centromeric and 1 2 dup (2) Fig. 1 . CGH and cytogenetic examination of tumor 991. CGH analysis showed a total chromosome 2 gain with an augmented 2q24-q34 region, and 2 partial karyotypes show 1 normal chromosome 2 and 2 copies of dup(2)(q24q34), resulting in pentasomy of the 2q24-q34 region. HOXD13 signals as expected, and 2 dup(2) chromosomes had 1 centromeric and 2 HOXD13 signals, which were apart. Cytogenetic, CGH and FISH findings indicated that the tumor cells had 5 copies of the 2q24-q34 region as a result of duplication of the 2q24-q34 region, and the subsequent duplication of the dup (2) Seven of the 11 N patients were treated with chemotherapy before surgery. To avoid the possible influence of chemotherapy, the 7 patients were excluded from the next analysis. The P values for EFS and OS were 0.0378 and 0.0503, respectively, among 4 N, 14 A1 and 13 A2 patients, and 0.0758 and 0.1126, respectively, among 4 N, 17 A3 and 10 A4 patients. The findings indicated that the differences in EFS and OS became more significant in the analysis excluding the 7 N patients than in the analysis including them. 4 . Event-free survival curves for 3 groups of patients classified by CGH and cytogenetic findings (log-rank, P=0.0549). N patients had no DNA copy changes and normal karyotypes or no mitotic cells. A1 patients had 2q gain, and A2 patients had DNA copy and/or cytogenetic changes other than 2q. N (11), A2 (13), A1 (14).
----Survival analyses on 3 groups of patients classified only by chromosome findings showed no differences among 13 N, 12 A1 and 4 A2 patients; 9 patients, whose tumors had no mitotic cells, were excluded from the analysis. The analysis on 3 groups of patients classified only by CGH findings showed a difference in OS (P=0.0356), but no difference in EFS (P=0.1724) among 14 N, 11 A1 and 13 A2 patients. Thus, the CGH analysis is more useful than the chromosome analysis to detect prognostic subgroups among hepatoblastoma patients.
Patients were grouped on the basis of various factors, including age (<5 years vs. ≥5 years), stage of the disease (I+II vs. III+IV), histological type of tumor (fetal histologic type vs. other types) and presence or absence of 2q gain (A1 patients vs. A2 patients; A1 patients vs. N patients). Cytogenetic and CGH classification 1 (N, A1, and A2), which showed a more significant P value on survival analysis than cytogenetic and CGH classification 2 (N, A3, and A4), was chosen for multivariate analysis on prognosis. The findings are summarized in Table III . Since no differences in EFS and OS were found between patients with and without fetal histologic type (data not shown), the histologic type was excluded from multivariate analysis. The patient's age and the groups classified by the cytogenetic and CGH classification had a similar contribution to the EFS. The patient's age had the largest contribution to the OS, followed by the cytogenetic and CGH classification and the stage of the disease. The findings show that the cytogenetic and CGH classification is an independent prognostic factor.
DISCUSSION
We examined 38 hepatoblastomas by both cytogenetic and CGH methods. CGH analysis detected the presence or absence of DNA copy changes in all 38 tumors including 9 that showed no mitotic cells by cytogenetic analysis. Moreover, CGH analysis detected DNA copy changes in 7 of 13 tumors that showed only normal mitotic cells; malignant cells may not have been in the mitotic phase, or were overlooked in the 7 tumors by cytogenetic analysis. However, cytogenetic analysis detected cells with chromosome abnormalities in 3 tumors that showed normal CGH pattern; the coexistence of tumor cells and an overwhelming number of non-tumor cells, which may have obscured the DNA copy changes, may explain the discrepancy. Thus, although CGH analysis gives more information on DNA copy changes than cytogenetic analysis, cytogenetic analysis sometimes complements CGH analysis.
By combined cytogenetic and CGH analysis we confirmed the findings previously reported that the most frequent chromosomal regions for DNA copy gain were 1q and 2q. [2] [3] [4] [5] [6] [7] [8] Frequent gain of 1q has been reported in various embryonal tumors and adult carcinomas by both cytogenetic and CGH analyses. 21, 22) In contrast, frequent gain of 2q has been reported only in ovarian carcinoma by CGH analysis. 23) Recently, three groups of investigators reported frequent gain of 2/2q in hepatoblastomas by [6] [7] [8] Two of them reported high-level gain in a restricted region at 2q24. 7, 8) The present study also showed a partial 2q gain in 6 tumors by CGH analysis, and identified 2q24 as the most common region for DNA copy gain (Fig. 2) . Furthermore, FISH and cytogenetic analysis revealed that the clone covering HOXD13 (2q31) was located outside the common region for the gain, and that partial 2q gain detected by CGH was produced by a cytogenetic mechanism of duplication of the 2q24-q34 region followed by duplication of dup(2) chromosome in one tumor (No. 991). These findings suggest that a gene located at 2q24 may have multiplied and increased its product, and given the hepatoblastoma cells the growth advantage needed for proliferation. Candidate genes at 2q24 included the activin receptor-like kinases (ALK) gene, the tumor necrosis factor receptor-associated factor (I-TRAF) gene and the FRZB-1 gene. [24] [25] [26] The HOXD genes, which are located close to the common region, 19) were excluded from candidacy by the present study.
In the present series of hepatoblastoma patients, EFS was lowest in A1 patients, highest in N patients and intermediate in A2 patients (Fig. 4) . Seven (64%) of 11 N and 19 (70%) of 27 A patients received preoperative chemotherapy, and the ratios of treated to untreated patients with chemotherapy were similar between N and A patients. The absence of DNA copy changes found in the 7 N patients who were given preoperative chemotherapy may be interpreted as indicating that their tumor cells had no DNA copy changes detectable by CGH before chemotherapy, or that most tumor cells with DNA copy changes were killed by chemotherapy and non-tumor cells predominated in the tissue samples. We showed that the differences in EFS and OS among the 3 groups of patients became more significant in the survival analysis excluding the 7 N patients than in the analysis including them. Multivariate analysis showed 2q gain as an independent factor predicting a poor outcome. These findings further suggest that a growth-promoting gene or an oncogene may be present at 2q24.
Recently, Weber et al. compared an incidence of gains of 1q, 2q, 8q, 20, or 22q, or loss of 4q between 26 patients with no evidence of disease and 8 patients who died of disease, and found gains of 8q and 20 as predictors of poor outcome. 8) In contrast to their findings, we found gain of 2q, but not gains of 8q and 20, as a prognostic factor for poor outcome using log-rank tests of survival curves depicted by the Kaplan-Meier method. The different patient populations or different statistical methods used to analyze the prognostic significance of chromosome gains between the 2 studies may have contributed to the discrepancy. Because 2q gain showed a borderline significance in the survival analysis of the present study, further studies including more patients than those in the present series are required to prove the prognostic implication of gain of 2q, or other chromosomal regions.
Loss of a chromosome region detected by CGH was rather rare in the present series of hepatoblastomas. Four patients had either unbalanced 1;4 translocations resulting in the loss of terminal 4q detected by cytogenetic analysis, or loss of 4q21-qter or 4q33 or 34-qter detected by CGH analysis. Previous cytogenetic and CGH studies reported similar unbalanced 1;4 translocations in 5 hepatoblastomas, and loss of chromosome 4 in 6 hepatoblastomas, respectively. 2-4, 7, 8) Taken together, the terminal 4q is the most frequent region for chromosome loss, and is the target site for the molecular cloning of a tumor suppressor gene responsible for the development of hepatoblastoma.
Patients with familial adenomatous polyposis coli, which is caused by germline mutation of the APC gene, have an increased incidence of hepatoblastoma, 10) and somatic mutation of the APC gene was reported in some sporadic hepatoblastomas. 11, 12) The APC protein targets for β-catenin degradation. 27) Recently, a high frequency of β-catenin mutation has been reported in sporadic hepatoblastomas. 13) However, the present cytogenetic and CGH study showed no loss of 5q and no gain of 3p, where APC and β-catenin genes are located, respectively.
